Rixubis (coagulation factor IX (recombinant)) for the Treatment of Haemophilia B

Rixubis [coagulation factor IX (recombinant)] is indicated for the control and prevention of bleeding episodes and perioperative management in the treatment of adult patients suffering from haemophilia B.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news